// App-Quantinova.ai

: Outcomes after Third Party, Viral-Specific, Cytotoxic Lymphocytes for Immunosuppression- and Epstein-Barr Virus-Associated Lymphoproliferative Disease

Researchers

Presenter

  • Sajida Kazi

Principal Investigators

  • Abhinav Mathur

  • Gwen M. Wilkie

  • Kirsty Cheal

  • Richard Battle

  • Neil McGowan

  • Emily Jane Hargreaves

  • David Turner

  • John D.M. Campbell

  • Marc Turner

  • Mark A Vickers

Medical Centers

  • Aberdeen Royal Infirmary, Aberdeen, United Kingdom

  • University of Aberdeen, Aberdeen, Scotland, United Kingdom

  • Jack Copland Centre, Scottish National Blood Transfusion Service, Edinburgh, United Kingdom

  • Scottish National Blood Transfusion Service, Aberdeen, United Kingdom

  • Edinburgh Royal Infirmary, Scottish National Blood Transfusion Service, Edinburgh, United Kingdom

  • Blood Transfusion Centre, ABERDEEN, United Kingdom

  • Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Autoimmune (AI)

Disease

  • Diffuse large B-cell lymphoma

  • Acute lymphoblastic leukemia

  • Lupus

  • Lympho proliferative disease

  • B cell lymphomas

  • T-cell lymphoma

  • Lymphomas

  • Graft-versus-host disease

Biomarkers

  • N/A

Drug/Treatment

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved